Ocumension Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Ocumension Therapeutics' CEO is Victor Liu, appointed in Aug 2018, has a tenure of 6.25 years. total yearly compensation is CN¥5.94M, comprised of 71.5% salary and 28.5% bonuses, including company stock and options. directly owns 4.14% of the company’s shares, worth HK$186.46M. The average tenure of the management team and the board of directors is 3.8 years and 5 years respectively.

Anahtar bilgiler

Victor Liu

İcra Kurulu Başkanı

CN¥5.9m

Toplam tazminat

CEO maaş yüzdesi	71.5%
CEO görev süresi	6.3yrs
CEO sahipliği	4.1%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	5yrs

Son yönetim güncellemeleri

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23

CEO Tazminat Analizi

Victor Liu'un ücretlendirmesi Ocumension Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥323m
Mar 31 2024	n/a	n/a	-CN¥351m
Dec 31 2023	CN¥6m	CN¥4m	-CN¥380m
Sep 30 2023	n/a	n/a	-CN¥399m
Jun 30 2023	n/a	n/a	-CN¥418m
Mar 31 2023	n/a	n/a	-CN¥411m
Dec 31 2022	CN¥5m	CN¥3m	-CN¥403m
Sep 30 2022	n/a	n/a	-CN¥393m
Jun 30 2022	n/a	n/a	-CN¥383m
Mar 31 2022	n/a	n/a	-CN¥322m
Dec 31 2021	CN¥5m	CN¥4m	-CN¥260m

Tazminat ve Piyasa: Victor's total compensation ($USD838.17K) is above average for companies of similar size in the Hong Kong market ($USD399.57K).

Tazminat ve Kazançlar: Victor's compensation has increased whilst the company is unprofitable.

CEO

Victor Liu (53 yo)

6.3yrs

Görev süresi

CN¥5,943,000

Tazminat

Mr. Ye Liu, also known as Victor, serves as Chief Executive Officer at Ocumension Therapeutics since joining on August 1, 2018 and has been its Executive Director since November 23, 2018. Mr. Liu is respon...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ye Liu	CEO & Executive Director	6.3yrs	CN¥5.94m	4.14% HK$ 186.5m
Zhaopeng Hu	Chief Development Officer & Executive Director	4.4yrs	CN¥2.21m	0.46% HK$ 20.6m
Tim Ruan	CFO & Joint Company Secretary	1.8yrs	Veri yok	Veri yok
DongHong Chen	Chief Medical Officer	5.1yrs	Veri yok	Veri yok
Qinglei Zuo	Chief Commercial Officer	3.8yrs	Veri yok	Veri yok
NA NA	Chief Medical Officer	less than a year	Veri yok	Veri yok
Tingchan Chen	Joint Company Secretary	1.2yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

45.5yo

Ortalama Yaş

Deneyimli Yönetim: 1477's management team is considered experienced (3.8 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ye Liu	CEO & Executive Director	6yrs	CN¥5.94m	4.14% HK$ 186.5m
Zhaopeng Hu	Chief Development Officer & Executive Director	4.6yrs	CN¥2.21m	0.46% HK$ 20.6m
Yanling Cao	Non-Executive Director	5.4yrs	Veri yok	Veri yok
Ting Yuk Wu	Independent Non-Executive Director	4.4yrs	CN¥720.00k	Veri yok
Lian Yong Chen	Non-Executive Chairman of the Board	6.5yrs	Veri yok	10.79% HK$ 485.9m
Zhenyu Zhang	Independent Non-Executive Director	2.6yrs	CN¥135.00k	Veri yok
Yiran Huang	Independent Non-Executive Director	4.4yrs	CN¥180.00k	Veri yok
Wei Li	Non-Executive Director	6.6yrs	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1477's board of directors are considered experienced (5 years average tenure).

Ocumension Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Recent updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

New minor risk - Profitability

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Consensus forecasts updated

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Consensus forecasts updated

Forecast to breakeven in 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China

Consensus forecasts updated

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China